"TAU PROTEIN A BETA-AMYLOID JAKO DIAGNOSTICK\u00C9 MARKERY ALZHEIMEROVY DEMENCE (Pilotn\u00ED studie)"@cs . "Podiv\u00EDnsk\u00FD, Ji\u0159\u00ED" . . "1212-0383" . "Mare\u0161, Jan" . . "Schneiderka, Petr" . "5"^^ . . "100" . "Tau Protein and Beta-amyloid as Diagnostic Markers for Alzheimer\u00B4s Disease (Pilot Study)"@en . "RIV/61989592:15110/04:00000910!RIV/2005/MZ0/151105/N" . "RIV/61989592:15110/04:00000910" . "589552" . "\u010Cesk\u00E1 a slovensk\u00E1 psychiatrie" . "Urb\u00E1nek, Karel" . . "Tau Protein and Beta-amyloid as Diagnostic Markers for Alzheimer\u00B4s Disease (Pilot Study)"@en . "7"^^ . "[13072E457DDE]" . "Bek\u00E1rek, Vojt\u011Bch" . "31-35" . . "15110" . "Herzig, Roman" . "TAU PROTEIN A BETA-AMYLOID JAKO DIAGNOSTICK\u00C9 MARKERY ALZHEIMEROVY DEMENCE (Pilotn\u00ED studie)"@cs . "CZ - \u010Cesk\u00E1 republika" . . "Backround: Several studies were performed focused on the possibilities to utilize biochemical markers in the diagnostics of Alzheimer disease (AD) during the last year. Tau protein level increase, and beta-amyloid (1-42) level decrease were found in the cerebrospinal fluid (CSF) in AD patients.Methods: In a hospital based study, laboratory assessment of tau protein and beta-amyloid (1-42), CSF levels was performed in 21 patients with dementia, and a control group of 21 patients with multiple sclerosis (MS). Genetic typing of apolipoprotein APO E, and comparison of the result of both biochemical, and genetic examinations were also performed in dementia patients. Results: Tau protein CSF leve was elevated in 67% of AD patients, 67% of patients wirh vascular dementia (VD), and 17% patients with mixed type of dementia (MD). Beta-amyloid(1-42) CSF level decrease was present in 67% of AD, 33% of VD, and 33% of MD patients. Concurrent tau protein level increase and beta-amyloid level decrease was found"@en . . . . "P(NF7480)" . . . . "\u00DAvod: Ve studi\u00EDch v\u011Bnovan\u00FDch diagnostice Alzheimerovy demence (AD) bylo zji\u0161t\u011Bno zv\u00FD\u0161en\u00ED hladiny tau proteinu a naopak sn\u00ED\u017Een\u00ED hladiny beta-amyloidu(1-42) v likvoru t\u011Bchto pacient\u016F oproti norm\u00E1ln\u00EDm hodnot\u00E1m a kontroln\u00EDm skupin\u00E1m. Tyto dva analyty p\u0159edstavuj\u00ED podle prob\u011Bhl\u00FDch studi\u00ED spole\u010Dn\u011B vhodn\u00FD marker pro v\u010Dasnou diagnostiku AD.Metodika:Hladina tau proteinu a beta-amyloidu(1-42) v likvoru byla vy\u0161et\u0159ena v souboru 21 pacient\u016F s demenc\u00ED a v kontroln\u00EDm souboru 21 pacient\u016F s roztrou\u0161enou skler\u00F3zou. U pacient\u016F s demenc\u00ED byly rovn\u011B\u017E provedeny genotypizace apolipoproteinu Apo E a porovn\u00E1n\u00ED v\u00FDsledk\u016F biochemick\u00FDch a genetick\u00FDch vy\u0161et\u0159en\u00ED s typem demence stanoven\u00FDm klinick\u00FDm vy\u0161et\u0159en\u00EDm.V\u00FDsledky: Hladina tau proteinu v likvoru byla zv\u00FD\u0161en\u00E1 u 67% pacient\u016F s AD, 67% vaskul\u00E1rn\u00EDch demenc\u00ED (VD) a 17% sm\u00ED\u0161en\u00FDch demenc\u00ED (SD). Sn\u00ED\u017Een\u00ED hladiny beta-amyloidu(1-42) bylo p\u0159\u00EDtomno u 67% AD, 33% VD a 33% SD. Sou\u010Dasn\u00E9 zv\u00FD\u0161en\u00ED tau proteinu a sn\u00ED\u017Een\u00ED beta-amyloidu(1-42) bylo nalezeno u 50% AD, 22% VD a 0% SD. V kontrol" . . . "\u00DAvod: Ve studi\u00EDch v\u011Bnovan\u00FDch diagnostice Alzheimerovy demence (AD) bylo zji\u0161t\u011Bno zv\u00FD\u0161en\u00ED hladiny tau proteinu a naopak sn\u00ED\u017Een\u00ED hladiny beta-amyloidu(1-42) v likvoru t\u011Bchto pacient\u016F oproti norm\u00E1ln\u00EDm hodnot\u00E1m a kontroln\u00EDm skupin\u00E1m. Tyto dva analyty p\u0159edstavuj\u00ED podle prob\u011Bhl\u00FDch studi\u00ED spole\u010Dn\u011B vhodn\u00FD marker pro v\u010Dasnou diagnostiku AD.Metodika:Hladina tau proteinu a beta-amyloidu(1-42) v likvoru byla vy\u0161et\u0159ena v souboru 21 pacient\u016F s demenc\u00ED a v kontroln\u00EDm souboru 21 pacient\u016F s roztrou\u0161enou skler\u00F3zou. U pacient\u016F s demenc\u00ED byly rovn\u011B\u017E provedeny genotypizace apolipoproteinu Apo E a porovn\u00E1n\u00ED v\u00FDsledk\u016F biochemick\u00FDch a genetick\u00FDch vy\u0161et\u0159en\u00ED s typem demence stanoven\u00FDm klinick\u00FDm vy\u0161et\u0159en\u00EDm.V\u00FDsledky: Hladina tau proteinu v likvoru byla zv\u00FD\u0161en\u00E1 u 67% pacient\u016F s AD, 67% vaskul\u00E1rn\u00EDch demenc\u00ED (VD) a 17% sm\u00ED\u0161en\u00FDch demenc\u00ED (SD). Sn\u00ED\u017Een\u00ED hladiny beta-amyloidu(1-42) bylo p\u0159\u00EDtomno u 67% AD, 33% VD a 33% SD. Sou\u010Dasn\u00E9 zv\u00FD\u0161en\u00ED tau proteinu a sn\u00ED\u017Een\u00ED beta-amyloidu(1-42) bylo nalezeno u 50% AD, 22% VD a 0% SD. V kontrol"@cs . . . "Alzheimer\u00B4s disease;vascular dementia;beta-amyloid(1-42);tau protein;Apo E apolipoprotein;diagnostics"@en . . . . "TAU PROTEIN A BETA-AMYLOID JAKO DIAGNOSTICK\u00C9 MARKERY ALZHEIMEROVY DEMENCE (Pilotn\u00ED studie)" . "TAU PROTEIN A BETA-AMYLOID JAKO DIAGNOSTICK\u00C9 MARKERY ALZHEIMEROVY DEMENCE (Pilotn\u00ED studie)" . . "Pidrman, Vladim\u00EDr" . . "5"^^ . . "1" .